{"entity":{"id":"nct07634471","kind":"trial","name":"A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)","aka":[],"tldr":"A phase 2/3 trial testing MK-1045 in follicular lymphoma, now recruiting.","summary":"A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) is a phase 2/3 interventional study registered as NCT07634471, led by Merck Sharp & Dohme, and recruiting on the registry. Official title: A Phase 2/3 Randomised, Open-label Study of MK-1045 in Combination With Rituximab in Participants With 1L Follicular Lymphoma. Planned enrolment is 960 participants (estimated). The study started in 2026-06-22 and primary completion is expected in 2032-07-23. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT07634471","url":"https://clinicaltrials.gov/study/NCT07634471"}],"tags":["ctgov-ingest"],"related":[],"cancers":["follicular-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["mk-1045"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07634471","phase":"2/3","setting":"A Phase 2/3 Randomized, Open-label Study of MK-1045 in Combination With Rituximab in Participants With 1L Follicular Lymphoma","sponsor":"Merck Sharp & Dohme","started":"2026-06-22","startedType":"actual","enrolled":960,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07634471/","neighbours":{"cancer":[{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"}],"drug":[{"id":"mk-1045","kind":"drug","name":"MK-1045","route":"/drugs/mk-1045/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}